To assess the tumor-inhibitory effect of T cells in thymus-complemented chimeric mice, we evaluated the pharmacological efficacy of anti-PD-L1 antibody on B6-derived tumors, syngeneic to the donor, implanted into B6 ESC → Foxn1nu/nu chimeras, in consideration of the future application of thymus-complemented models to cancer immunology. The gene discussed is CD274; the disease is neoplasm.